Stock Detail
CUBIST PHARMACEUTICALS INC
Sector: Drug Manufacturers Other
Latest Quote @ Wed Jun 6 18:53:40 (15 min delayed)
| $50.00 |
$50.44 |
$49.97 |
-1.16 |
-2.27% |
|
Last Day's Data
| $51.13 |
$51.13 |
$1.16 |
2.32% |
0.00 |
$49.97 |
| $50.02 |
$49.82 |
683,394.00 |
3.33B |
739,858.00 |
29.01 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 52.00 |
51.56 |
50.69 |
50.25 |
49.38 |
Stock Profile
Cubist Pharmaceuticals, Inc. engages in the research, development, and commercialization of products for anti-infective and acute care needs market. Its principal product, Cubicin, is approved in the United States for the treatment of skin and skin structure infections caused by certain gram-positive bacteria. The company's pipeline includes HepeX-B, a monoclonal antibody biologic that is in second of two Phase 2 trials, for the prevention of infection by Hepatitis B virus in liver transplant patients, as well as research efforts focused on members of the lipopeptide class of molecules. Cubist has a licensing agreement with XTL Biopharmaceuticals, Ltd., for the development and commercialization of HepeX-B. The company was founded in 1992 and is headquartered in Lexington, Massachusetts.
